Navigation Links
Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
Date:5/5/2010

SAN DIEGO, May 5 /PRNewswire/ -- Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

The name ViaCyte retains the Company's identity as a leading cell therapy company, as "–cyte" is derived from the Greek "kytos," which means cell.  As the Company is moving towards the market, clear and unambiguous brand recognition is increasingly important.  With its new name, the Company has also adopted a new corporate logo.  An abstract flower emphasizes the rejuvenation possible through a stem cell-derived therapy.

The name ViaCyte was previously used by ViaCell, Inc., but their use was discontinued following acquisition of ViaCell by Perkin Elmer, Inc.  The Company has acquired all rights to the ViaCyte service marks and internet domain name addresses previously owned by ViaCell.  The Company's product developments are not related to those of ViaCell or Perkin Elmer.

The Company's new name also provides consolidation.  The Company is the result of a three-way merger in 2004 of Novocell, Inc. (Irvine, CA), CyThera, Inc. (San Diego, CA) and BresaGen, Inc. (Athens, GA).  Going forward, the Company is focused on stem cell innovations initiated in its San Diego and Athens locations, and has discontinued work on PEG-encapsulated islets that were the focus of its former Irvine location.  All of the Company's operations will use the ViaCyte name.  The Company's wholly owned subsidiary in Athens, Georgia will take the name ViaCyte Georgia.

About ViaCyte, Inc.

ViaCyte is a preclinical therapeutic company focused on diabetes.  Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells.  These cells are implanted using a durable and retrievable encapsulation device.  Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.  The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
2. Missouri Becomes the Fourth State to Connect to Kentuckys Real-time Cold Medicine Tracking System
3. Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System
4. US Oncology Foundation Becomes Life Beyond Cancer Foundation
5. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
6. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
7. Hope International Centro de Radioterapia of Guatemala Becomes First in Latin America to Treat Cancer Using RapidArc(R) Radiotherapy Technology From Varian Medical Systems
8. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
9. Merieux Alliance Becomes Institut Merieux
10. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
11. Triage Wireless, Inc. Becomes Sotera Wireless, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- A new survey from the American Association ... Program (CBP) significantly reduced beneficiary choice and access to ... forces beneficiaries to switch to unfamiliar or unsuitable testing ... AADE,s survey is the latest in a continuous ... the inherent problems with the CBP. Last year, a ...
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com ... Based ... adult use in states where cannabis is legal will generate $655 ... million will be from cannabis specific taxes, such as ... $96 million will be earned from state sales taxes that are ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... , ... The Case Management Society of America (CMSA) will install six new ... membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on ... Advisory position has also been added to the BOD, per an appointment made by ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... Foothill Ranch, California (PRWEB) , ... March 27, 2017 , ... ... company’s commitment to its customers. First National Capital has added 10 new sales professionals ... to grow its sales positions by 15 additional new hires over the course of ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):